title: Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa.
abstract: We administered cabergoline, a potent, once-a-day dopamine against, to 61 patients with advanced Parkinson's disease (PD) and response fluctuations--"wearing-off" and "on-off" phenomena. The patients were on stable doses of levodopa/carbidopa. During the first 5 weeks, patients were randomized to allow equal numbers to end titration at each of five daily doses of cabergoline from 0.5 to 2.5 mg. We evaluated the patients using the Unified Parkinson's Disease Rating Scale (UPDRS) and diaries of motor performance. This part of the study was double-blinded. After 5 weeks, the mean Activities of Daily Living (ADL) score on the UPDRS decreased by 22% (p < 0.0001), the mean Motor Score in the "off" period decreased by 14% (p < 0.0001), and the mean Motor Score in the "on" period decreased by 22% (p < 0.0001). The mean percent "off" time decreased by 9.0%. Twenty-three patients (38%) achieved at least a 25% improvement in the combined ADL and motor examination of the UPDRS. Four patients dropped out because of adverse effects. We treated 37 patients, including some patients who had experienced a transient 25% improvement, for an additional 8 weeks in an open manner until they achieved a 25% improvement or reached a maximum of 5 mg/d. The other patients were continued in a double-blind manner on the dose of cabergoline they had achieved at the end of week 5. At the end of 13 weeks, the group of 37 patients achieved additional significant improvements in mean ADL and mean motor scores in the "on" and "off" periods. The percent time "off" decreased by 31%.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Barrow Neurological Institute, St. Joseph's Medical Center, Phoenix, AZ 85013-4496.
authors.forename: A
authors.initials: A
authors.lastname: Lieberman
authors.forename: S
authors.initials: S
authors.lastname: Imke
authors.forename: M
authors.initials: M
authors.lastname: Muenter
authors.forename: K
authors.initials: K
authors.lastname: Wheeler
authors.forename: J E
authors.initials: JE
authors.lastname: Ahlskog
authors.forename: J Y
authors.initials: JY
authors.lastname: Matsumoto
authors.forename: D M
authors.initials: DM
authors.lastname: Maraganore
authors.forename: K F
authors.initials: KF
authors.lastname: Wright
authors.forename: J
authors.initials: J
authors.lastname: Schoenfelder
mesh_terms: D000328:Adult; D000368:Aged; D000077465:Cabergoline; D002230:Carbidopa / Q000627:therapeutic use*; D015259:Dopamine Agents / Q000627:therapeutic use*; D004338:Drug Combinations; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009043:Motor Activity / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D011954:Receptors, Dopamine / Q000187:drug effects
chemical_list: D015259:Dopamine Agents; D004338:Drug Combinations; D004873:Ergolines; D011954:Receptors, Dopamine; D007980:Levodopa; D000077465:Cabergoline; D002230:Carbidopa